Analysis of TPE Treatments With multiFiltratePRO

NCT06272084 · tracked via the Priya Life Science Germany tracker

Sponsor

Fresenius Medical Care Deutschland GmbH

Phase

Observational

Started

2024-05-22

Last updated

2026-09-11

Condition(s) studied

Autoimmune Diseases

Investigational drug(s) / intervention(s)

Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO

Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO: Retrospective Data Analysis of TPE treatments with multiFiltratePRO

Study summary

Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Body weight ≥40kg irrespective of the age * Patients with indication for TPE treatment according to ASFA guideline * Patients have been treated with TPE between January 2019 and October 2023 * Availability of at least 50% of the parameters to be documented for the patient Exclusion Criteria: * Participation in an interventional clinical study during the retrospectively collected TPE treatment data * Previous documentation within this study * Simultaneous use of another filter for additional therapy form

Primary outcome measure(s)

Total amount of exchange plasma (prescribed vs achieved exchange volume) — through study completion, an average of 1 year
Statistical analysis is performed on retrospective data (Treatments between 2019 and October 2023). Primary goal of the study is to prove that the prescribed therapeutic plasma exchange rate during treatment was achieved in \> 70% of treatments and therefore was in alignment with current guidelines.

Trial sites (3)

Facility	City	Region
Klinikum Aschaffenburg-Alzenau	Aschaffenburg	Bavaria
Universitätsklinikum Würzburg	Würzburg	Bavaria
Charité-Universitätsmedizin Berlin	Berlin	State of Berlin

More Fresenius Medical Care Deutschland GmbH trials in Germany

Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation Starting soon

PD Catheter Data Collection Recruiting

Clinical Performance of the New Plasma Filter PX2 in TPE Treatments Recruiting

Analysis of Paediatric Treatments With multiFiltratePRO Recruiting

Other trials for the same condition

Natural History of Type 1 Interferonopathies: Insights From a European Cohort Recruiting

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies Enrolling by invitation

Clinical Performance of the New Plasma Filter PX2 in TPE Treatments Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06272084 on ClinicalTrials.gov ↗ ← All trials in Germany